Press release from Companies

Published: 2020-11-09 15:30:26

WntResearch AB: Anders Tidfors new CFO of WntResearch

Anders Tidfors has a strong background including several CFO assignments, both nationally and internationally. With considerable experience from leading financial roles, Tidfors will strengthen WntResearch in executing the Company's clinical programs with the drug candidate Foxy-5. Tidfors will take up appointment in mid-November, initially combining part-time work for WntResearch with other assignments, including work for a listed company.

"I look forward to continue to develop WntResearch's organization, financial control and positioning together with Anders to implement the company's ongoing development program with Foxy-5 in an effective manner. With an intense and challenging period ahead of us, is it most gratifying to be able to welcome Anders to WntResearch," says acting CEO Anders Rabbe.

For more information, please contact:

Anders Rabbe, Acting CEO, WntResearch AB

Telephone: +46 707 646500

About WntResearch

WntResearch is a research and development company in oncology that develops new treatments intended to inhibit metastasis formation in cancers. The Company focuses on WNT5A, a protein that suppresses the metastatic process in the body; the vision is for cancer patients to no longer have to endure metastasis. Today, one in every three people will develop cancer during their lifetimes, and 90 percent of all cancer-related deaths are caused by metastases. Even though cancer treatment has become more effective, there are no effective methods to prevent the formation of metastasis. The drug candidate Foxy-5 mimics WNT5A’ s ability to reduce the mobility and thus the spread of cancer cells. Foxy-5 has demonstrated a good safety profile with few adverse effects in two clinical phase I studies. An ongoing clinical phase II study is currently being conducted on patients with colon cancer with the Company's drug candidate Foxy-5. According to the Company's assessment, Foxy-5 is the only drug candidate of its kind, with a unique mode of action in an area where other drug or treatment options are lacking. WntResearch’s share is listed on Spotlight Stock Market. For more information, please visit:

Läs mer hos Cision
Read more about WntResearch AB